PIPA525339

TRAG3 Polyclonal Antibody, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIPA525339-Each-of-1 In Stock ₹ 46,502.50

PIPA525339 - Each of 1

₹ 46,502.50

In Stock

Quantity

1

Base Price: ₹ 46,502.50

GST (18%): ₹ 8,370.45

Total Price: ₹ 54,872.95

Antigen

TRAG3

Classification

Polyclonal

Conjugate

Unconjugated

Gene

CSAG2

Gene Alias

cancer/testis antigen 24.2; cancer/testis antigen family 24, member 2; chondrosarcoma-associated gene 2/3 protein; chondrosarcoma-associated gene 2/3 protein-like; CSAG family member 2; CSAG family, member 3B; CSAG2; CSAG3B; CT24.2; MGC149851; MGC149852; taxol resistance associated gene 3; taxol-resistant-associated gene 3 protein; trag 3; TRAG3; TRAG-3

Host Species

Rabbit

Purification Method

Antigen affinity chromatography, Protein A

Regulatory Status

RUO

Gene ID (Entrez)

102723547

Content And Storage

-20° C, Avoid Freeze/Thaw Cycles

Form

Liquid

Applications

Immunohistochemistry (Paraffin), Western Blot

Concentration

0.5 mg/mL

Formulation

PBS with 0.09% sodium azide

Gene Accession No.

Q9Y5P2

Gene Symbols

CSAG2

Immunogen

KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human CSAG2

Quantity

400 μL

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG

Related Products

Img

Thermo Scientific

PIPA524701

--

Img

Thermo Scientific

PIPA525681

--

Img

Thermo Scientific

PIPA526941

--

Img

Thermo Scientific

PIPA525417

--

Img

Thermo Scientific

PIPA525749

--

Img

Thermo Scientific

PIPA525058

--

Img

Thermo Scientific

PIPA524718

--

Img

Thermo Scientific

PIPA524910

--

Description

  • The expression of the cancer-testis antigen Taxol resistanceassociated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma
  • Overexpressed in taxolresistant breast cancer line MDA 435(TR) and the doxorubicinresistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR (10)V
  • Weakly expressed in kidney
  • TRAG-3 is an attractive target for immunotherapy of cancer.